12/17/2018 9:57:16 AM
US Patent Office Awards Diffusion Rights For Use Of TSC In Conjunction With Only FDA-Approved Stroke Therapeutic
11/14/2018 9:06:44 AM
Diffusion Pharma Q3 Loss/shr $0.13 Vs. EPS $0.20 Prior Year
9/12/2018 9:05:01 AM
FDA Oks Start Of Innovative On-Ambulance Phase 2 Trial For Treatment Of Acute Stroke By Diffusion Pharma
8/13/2018 8:34:57 AM
Diffusion Pharma H1 Net Cash Used In Operating Activities $5.8 Mln Vs $6.2 Mln Last Year
6/12/2018 8:43:54 AM
Diffusion Pharma Announces Validation Of European Patent For Oral Formulations Of TSC
2/1/2018 8:15:43 AM
Diffusion Announces Allowances Of Two U.S. Patent Applications
1/18/2018 6:01:52 AM
Diffusion Pharma Prices Underwritten Public Offering Of 15 Mln Common Shares At $0.80/Shr
1/10/2018 8:52:20 AM
Orphan Rare Diseases R&D Advancements Increase Novel Therapeutic Options For Drug Development Pipeline